Indications
Secondary prevention of atherothrombotic complications (in combination with ASA) in patients with acute coronary syndrome:
In adult patients after a recent myocardial infarction (from a few days to 35 days), a recent ischemic stroke (from 7 days to 6 months), or with diagnosed occlusive peripheral arterial disease, clopidogrel administration reduced the frequency of the combined endpoint, which included repeated ischemic stroke (with or without lethal outcome), repeated myocardial infarction (with or without lethal outcome) and other cardiovascular death & nbsp;
In adult patients with acute coronary syndrome:
- acute coronary syndrome without ST segment elevation (unstable angina pectoris / myocardial infarction without Q wave), including patients who should receive medical treatment and patients who are indicated for percutaneous coronary intervention (with or without stenting) or coronary artery bypass grafting (CABG). Clopidogrel intake reduced the incidence of the combined endpoint, which included cardiovascular death, myocardial infarction, or stroke, as well as the incidence of the combined endpoint, which included cardiovascular death, myocardial infarction, stroke, and refractory ischemia.
- acute myocardial infarction with ST segment elevation. Clopidogrel supplementation reduced all-cause mortality and the incidence of a combined endpoint that included death, recurrent myocardial infarction, or stroke.
Prevention of atherothrombotic and thromboembolic complications in adult patients with atrial fibrillation (atrial fibrillation).
It has been shown that in patients with atrial fibrillation with an increased risk of vascular complications, therapy with indirect anticoagulants that are vitamin K antagonists (VKA) is associated with greater clinical benefit compared to the use of ASA alone or a combination of clopidogrel with ASA in terms of reducing the risk of stroke.
Patients with atrial fibrillation (atrial fibrillation) who have at least one risk factor for the development of vascular complications who cannot take VKA (for example, if there is a special risk of bleeding, the patient's inability, in the opinion of the attending physician, to adequately control the INR (international normalized ratio) or if the patient does not accept VKA treatment), clopidogrel in combination with ASA is indicated to prevent atherothrombotic and thromboembolic complications, including stroke.
It was shown that clopidogrel in combination with ASA reduced the incidence of the combined endpoint, which included stroke, myocardial infarction, systemic thromboembolism outside the central nervous system, or cardiovascular death, mainly by reducing the incidence of stroke & nbsp.